Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Here, we describe the surprising residual capability of the Rb pathway to negatively regulate proliferation and tumorigenesis in a SV40 large T antigen (Tag)-driven mouse model of pancreatic islet carcinogenesis. Heterogeneous Tag expression during all progression stages suggested that a threshold level of the T antigen oncoprotein might be deterministic for beta-cell hyperproliferation and led us to hypothesize that Tag might not be fully inhibiting the tumor suppressor activity of Rb. Moreover, genomic profiling of these tumors by array CGH pointed to regions of loss on chromosomes 6 and 14, where the Rb pathway inhibitor p27 and Rb itself, respectively, reside. Indeed, genetic ablation of the p27(Kip1) or Rb genes accentuated Tag-induced tumorigenesis, with loss of Rb in particular broadly enhancing multiple parameters of tumorigenesis including the frequency and growth rates of premalignant lesions, of nascent solid tumors, and of invasive carcinomas. The data indicate that attenuation rather than complete inactivation of Rb tumor suppressor gene function, in the context of p53 inhibition, is sufficient to initiate tumorigenesis in this model of islet cell cancer, with the demonstrable possibility that subsequent losses of Rb or its regulators can enhance malignant progression. The results may be relevant to human papillomavirus (HPV)-induced cervical neoplasias where E7 oncogene expression levels or activity (in the case of intermediate/low-risk HPV subtypes) incompletely inhibits Rb tumor suppressor functions, as well as to other neoplasias where initiating oncogenic or tumor suppressor events reduce but do not abrogate Rb function.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The senescence phenotype is dependent on the p16-RB pathway, thus unlike the aforementioned Tag-driven hepatoma model, the residual RB activity seems to be sufficient for senescence induction in this model 129”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [129]
In the citing paper
“Although Tag binds both RB and p53, it attenuates, rather than fully inactivates, their activity, thus their residual activities allow the RIP-Tag2 mice to exhibit progressive tumorigenesis with only a small portion of islets developing invasive pancreatic cancer 127,129”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [129]
Citations
Cites
Effects of an Rb mutation in the mouse
Jacks, T., Fazeli, A., Schmitt, E. M., Bronson, R. T., Goodell, M. A., & Weinberg, R. A. (1992) · Nature · doi:10.1038/359295a0 · Cited by 1,755 · cited 1×
“…to tumorigenesis in the context of loss of Rb, as shown by the fact that Rb germline knockout heterozygote mice also develop pituitary tumors (Jacks et al., 1992) and by the high incidence of pituitary tumors in familial retinoblastoma mutations, clinically called trilateral retinoblastoma…”
BackgroundOpenings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Self-citationHanahan, D. (1985) · Nature · doi:10.1038/315115a0 · Cited by 1,281
Self-citationBergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192
Marino, S., Vooijs, M., van der Gulden, H., Jonkers, J., & Berns, A. (2000) · Genes & Development · doi:10.1101/gad.14.8.994 · Cited by 920
Beta-cell adaptation and decompensation during the progression of diabetes
Weir, G. C., Laybutt, D. R., Kaneto, H., Bonner-Weir, S., & Sharma, A. (2001) · Diabetes · doi:10.2337/diabetes.50.2007.s154 · Cited by 462 · cited 1×
“…Smith and D Hanahan, unpublished results); second, the fact that proliferating b cells have been shown to downmodulate insulin gene transcription (Weir et al., 2001) and similarly may decrease insulin promoter-driven Tag expression; and third, the possibility of cell-to-cell variations in…”
BackgroundA second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis
Christofori, G., Naik, P., & Hanahan, D. (1994) · Nature · doi:10.1038/369414a0 · Cited by 390 · cited 2×
“In addition, the initial proliferative switch that initiates this pathway to islet carcinomas involves the focal activation of expression of IGF-2, which acts initially as a survival factor (Christofori et al., 1994).”
BackgroundSelf-citationInoue, M., Hager, J. H., Ferrara, N., Gerber, H.-P., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00031-4 · Cited by 380 · cited 1×
“BrdU, TUNEL staining and H&E grading were performed as described previously (Inoue et al., 2002; Lopez and Hanahan 2002).”
MethodSelf-citationGenome scanning with array CGH delineates regional alterations in mouse islet carcinomas
Hodgson, G., Hager, J. H., Volik, S., Hariono, S., Wernick, M., Moore, D., Albertson, D. G., Pinkel, D., Collins, C., Hanahan, D., et al. (2001) · Nature Genetics · doi:10.1038/ng771 · Cited by 294
Self-citationLopez, T., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00055-7 · Cited by 268 · cited 5×
“This effect is more readily apparent in the more frequent IT and IC1 category, and less apparent in the IC2 category possibly due to the comparatively low frequency of the IC2 lesions, or the hypothesized different pathways of origin for the IC1 and IC2 tumors (Lopez and Hanahan 2002).”
BackgroundMethodInfluentialSelf-citationHeterogeneity in Pancreatic β-cell Population
Pipeleers, D. G. (1992) · Diabetes · doi:10.2337/diab.41.7.777 · Cited by 212 · cited 1×
“…et al., 2001) and similarly may decrease insulin promoter-driven Tag expression; and third, the possibility of cell-to-cell variations in glucose sensitivity and levels of endogenous insulin II gene expression (Pipeleers 1992), which may similarly affect the insulin II promoter-driven transgene.”
BackgroundRole of T antigen interactions with p53 in tumorigenesis
Pipas, J. M., & Levine, A. J. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0343 · Cited by 199 · cited 2×
“Based on the extensive studies into the capability of Tag to inhibit Rb function both in cell culture and in in vivo animal models (Pipas and Levine, 2001), we favor the former hypothesis.”
ResultGannon, M., Shiota, C., Postic, C., Wright, C. V. E., & Magnuson, M. (2000) · genesis · doi:10.1002/(sici)1526-968x(200002)26:2<139::aid-gene12>3.0.co;2-7 · Cited by 169 · cited 3×
“RIP2-Cre transgenic mice, kindly provided by Mark Magnuson (Vanderbilt University Medical Center, Nashville, TN, USA) (Gannon et al., 2000), were previously backcrossed into the C57-Bl/6J background for more than 15 generations.”
BackgroundMethodInfluentialFerguson, K. L., Vanderluit, J. L., Hébert, J. M., McIntosh, W. C., Tibbo, E., MacLaurin, J. G., Park, D. S., Wallace, V. A., Vooijs, M., McConnell, S. K., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf338 · Cited by 156
Bader, J., Miller, R. C., Meadows, A., Zimmerman, L. E., Champion, L. A., & Voûte, P. A. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92009-7 · Cited by 122
Transforming functions of Simian Virus 40
Sáenz-Robles, M. T., Sullivan, C. S., & Pipas, J. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204936 · Cited by 98 · cited 1×
“This result is also consistent with other studies that have shown Tag binding to p53 both inhibits p53 function while increasing abundance of p53 protein by limiting its MDM2-dependent degradation (Pipas and Levine, 2001; Saenz-Robles et al., 2001).”
ResultSang, B., & Barbosa, M. S. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.17.8063 · Cited by 89 · cited 2×
“…variants of the E6 and E7 oncogenes that are not able to fully inhibit Rb and p53, rather only partially attenuating their tumor suppressor functions, although they are also able to trigger cervical carcinoma after a long latency period (Sang and Barbosa 1992; Giannoudis and Herrington, 2000).”
BackgroundShields, J. A., Pesin, S. R., & Shields, C. L. (1989) · PubMed · Cited by 82
Brownstein, S. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030207028 · Cited by 42
Heterogeneity in pancreatic beta-cell population
PIPELEERS, D. G. (1992) · Diabetes · doi:10.2337/diabetes.41.7.777 · Cited by 36
Efrat, S., Bækkeskov, S., Lane, D. P., & Hanahan, D. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02562.x · Cited by 29
Self-citationAn Unexpected Role for p53 in Augmenting SV40 Large T Antigen-Mediated Tumorigenesis
Herzig, M., Novatchkova, M., & Christofori, G. (1999) · Biological Chemistry · doi:10.1515/bc.1999.028 · Cited by 26
Hager, J. H., Hodgson, J., Fridlyand, J., Hariono, S., Gray, J. W., & Hanahan, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3522 · Cited by 25
Self-citationNakagawa, S., Yoshikawa, H., Jimbo, H., Onda, T., Yasugi, T., Matsumoto, K., Kino, N., Kawana, K., Kozuka, T., Nakagawa, K., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690181 · Cited by 14 · cited 1×
“…HPV cancers develop mutations in the p53 tumor suppressor gene more frequently than in the high-risk HPV cancers (Lo et al., 1992; Nakagawa et al., 1999; Kim et al., 2001), suggesting that attenuation instead of complete inhibition of this tumor suppressor gene selects for…”
BackgroundHigher incidence of p53 mutation in cervical carcinomas with intermediate-risk HPV infection
Kim, H.-J., Song, E., & Hwang, T.-S. (2001) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(01)00309-8 · Cited by 10 · cited 1×
“…develop mutations in the p53 tumor suppressor gene more frequently than in the high-risk HPV cancers (Lo et al., 1992; Nakagawa et al., 1999; Kim et al., 2001), suggesting that attenuation instead of complete inhibition of this tumor suppressor gene selects for secondary genetic or…”
BackgroundStage as major long term outcome predictor in minor salivary gland carcinoma
Lutgendorf (2000) · Pure Amsterdam UMC · doi:10.1002/1097-0142(20000915)89:6 · Cited by 1
Research works printed but not linked: 1
- Giannoudis A and Herrington CS . (2000). Cancer, 89, 1300–1307. · doi:10.1002/1097-0142(20000915)89:6<1300::aid-cncr15>3.0.co;2-u
Cited by
T-helper-1-cell cytokines drive cancer into senescence
Braumüller, H., Wieder, T., Brenner, E., Aßmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., et al. (2013) · Nature · doi:10.1038/nature11824 · Cited by 720
Inside and out: the activities of senescence in cancer
Pérez-Mancera, P. A., Young, A. R. J., & Narita, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3773 · Cited by 462
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers
Maser, R. S., Choudhury, B., Campbell, P. J., Feng, B., Wong, K.-K., Protopopov, A., O’Neil, J., Gutierrez, A., Ivanova, E., Perna, I., et al. (2007) · Nature · doi:10.1038/nature05886 · Cited by 377
Müller-Hermelink, N., Braumüller, H., Pichler, B., Wieder, T., Mailhammer, R., Schaak, K., Ghoreschi, K., Yazdi, A., Haubner, R., Sander, C. A., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.001 · Cited by 302
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer
Olson, P., Lu, J., Zhang, H., Shai, A., Chun, M. G., Wang, Y., Libutti, S. K., Nakakura, E. K., Golub, T. R., & Hanahan, D. (2009) · Genes & Development · doi:10.1101/gad.1820109 · Cited by 260
Self-citation
Metadata
- Authors
- Casanovas, O., Hager, J. H., Chun, M. G. H., & Hanahan, D.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Hanahan, Douglas
- Venue
- Oncogene
- Published
- 2005-06-27
- Volume
- 24
- Issue
- 44
- Pages
- 6597-6604
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2010314404
- Cited by
- 31
- References
- 26
- Citations by year
- 2023: 1 · 2022: 2 · 2020: 3 · 2019: 3 · 2018: 1 · 2017: 1 · 2014: 1 · 2013: 1
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- p53 inactivation, SV40 large T antigen, p27, malignant progression, HPV E7 oncogene, cervical neoplasia
- MeSH terms
- Animals, Humans, Immunohistochemistry, Islets of Langerhans, Mice, Transgenic, Pancreatic Neoplasms, Genes, Retinoblastoma, Mice, Knockout, Cell Cycle Proteins, Tumor Suppressor Proteins, Cell Proliferation, Cyclin-Dependent Kinase Inhibitor p27, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.